Gelonghui, December 4th丨haisco pharmaceutical group (002653.SZ) announced that its subsidiary tibet haisco pharmaceutical group recently received the "Notice of Approval for Clinical Trials of Pharmaceuticals" issued by the National Medical Products Administration. The tablet is named HSK46575 and is intended for the treatment of prostate cancer.
HSK46575 is an orally taken, highly potent, and selective small molecule inhibitor independently developed by the company, intended for the treatment of prostate cancer. Preclinical research results indicate that this product has a clear target, definite efficacy, and good safety, making it a small molecule drug with significant development potential. Its benefit/risk ratio in clinical application is high, and it has a broad clinical application prospect, expected to become an effective treatment for prostate cancer and solve the current problem of drug scarcity in clinical use.